Key result
Gabapentinoid initiation was associated with an increased risk of subsequent loop diuretic initiation compared to SNRIs (pooled ratio of adjusted sequence ratios 1.58; 95% CI 1.23-2.04).
Why the study?
To assess the gabapentinoid-oedema-loop diuretic prescribing cascade in adults using large administrative health care databases from the USA and Denmark.
Does initiation of gabapentinoids increase the risk of subsequent loop diuretic initiation in adults without heart failure or chronic kidney disease?
Observational (n=1,511,493)
Yes
Does initiation of gabapentinoids increase the risk of subsequent loop diuretic initiation in adults without heart failure or chronic kidney disease?
Relative Risk: 1.58 (95% CI 1.23–2.04)
Initiation of gabapentinoids is associated with a subsequent increase in loop diuretic prescriptions, indicating a prescribing cascade likely due to gabapentinoid-induced edema.
May indicate gabapentinoid-edema prescribing cascade; hypothesis-generating and requires randomized confirmation before practice change.
AIMS: To assess the gabapentinoid-oedema-loop diuretic prescribing cascade in adults using large administrative health care databases from the USA and Denmark. METHODS: This study used a sequence symmetry analysis to assess loop diuretic initiation before and after the initiation of gabapentinoids among patients aged 20 years or older without heart failure or chronic kidney disease. Data from MarketScan Commercial and Medicare Supplemental Claims databases (2005 to 2019) and Danish National Prescription Register (2005 to 2018) were analyzed. Use of loop diuretics associated with initiation of selective norepinephrine reuptake inhibitors (SNRI) was used as a negative control. We assessed the pooled temporality of loop diuretic initiation relative to gabapentinoid or SNRI initiation across the 2 countries. Secular trend-adjusted sequence ratios (aSRs) with 95% confidence intervals (CIs) were calculated using data from 90 days before and after initiation of gabapentinoids. Pooled ratio of aSRs were calculated by comparing gabapentinoids to SNRIs. RESULTS: Among the 1 511 493 gabapentinoid initiators (Denmark [n = 338 941]; USA [n = 1 172 552]), 20 139 patients had a new loop diuretic prescription 90 days before or after gabapentinoid initiation, resulting in a pooled aSR of 1.33 (95% CI 1.06-1.67). The pooled aSR for the negative control (i.e., SNRI) was 0.84 (95% CI 0.75-0.94), which resulted in a pooled ratio of aSRs of 1.58 (95% CI 1.23-2.04). Pooled estimated incidence of the gabapentinoid-loop diuretic prescribing cascade was 8.14 (95% CI, 1.92-34.49) events per 1000 patient-years. CONCLUSION: We identified evidence of the gabapentinoid-oedema-loop diuretic prescribing cascade in 2 countries.
No takes yet. Share an insight, caveat, or question.
Vouri et al. (2022) conducted an observational in Adults without heart failure or chronic kidney disease (n=1,511,493). Gabapentinoids vs. Selective norepinephrine reuptake inhibitors (SNRI) was evaluated on Loop diuretic initiation (Ratio of aSRs 1.58, 95% CI 1.23-2.04). Gabapentinoid initiation was associated with an increased risk of subsequent loop diuretic initiation compared to SNRIs (pooled ratio of adjusted sequence ratios 1.58; 95% CI 1.23-2.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: